

EVALUATION OF *RENNELIA ELLIPTICA* AS POTENTIAL ANTIPLASMODIAL HERBAL REMEDY

Che Puteh Osman^{a,b*}, Nor Hadiani Ismail^{a,b}, Rohaya Ahmad^{a,b}, Aty Widyawaruyanti^{c,d}, Lidya Tumewu^{c,d}, Chee Yan Choo^e, Sharinah Ideris^e

^aFaculty of Applied Sciences, Universiti Teknologi MARA, 40450 Shah Alam, Selangor, Malaysia

^bAtta-ur-Rahman Institute for Natural Product Discovery, Universiti Teknologi MARA, 42300 Bandar Puncak Alam, Selangor, Malaysia

^cDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60286, Indonesia

^dNatural Product Medicine Research and Development, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, Indonesia

^eMedChem Herbal Research Group, Faculty of Pharmacy, Universiti Teknologi MARA, 42300 Bandar Puncak Alam, Selangor, Malaysia

Article history

Received

4 November 2016

Received in revised form

6 June 2017

Accepted

10 August 2017

*Corresponding author
cheputeh
@salam.uitm.edu.my

Abstract

Rennellia elliptica (Rubiaceae) has been used by local Jakun Community in the Endau Rompin State Park for the treatment of jaundice. Previous study has revealed the antiplasmodial activity of the root extract and major anthraquinones isolated from the roots. The present study entails the optimization of extraction methods, qualitative and quantitative analyses of selected marker anthraquinones and *in vivo* antiplasmodial activity along with toxicity and inhibition of β -hematin *in vitro*. HPLC profile showed the present of marker compounds as major constituents with content ranging 3-12 $\mu\text{g/g}$ extract. The root extract showed potent antiplasmodial activity against rodent malaria, *Plasmodium berghei* with ED_{50} value of 1.23 $\mu\text{g/ml}$ BW. The major anthraquinones, damnacanthal and nordamnacanthal showed significant inhibition against β -hematin formation via lipids and HRP2 catalyses. However, the root extract is slightly toxic against hepatocyte cell. These data suggests that *R. elliptica* is a potential herbal remedy for malaria treatment and antiplasmodial of the root extract possibly due to the action of major anthraquinones.

Keywords: *Rennellia elliptica*, antiplasmodial, anthraquinones, *Plasmodium*, malaria

Abstrak

Rennellia elliptica (Rubiaceae) digunakan oleh masyarakat Jakun di Taman Negeri Endau Rompin untuk rawatan jaundis. Kajian terdahulu menunjukkan ekstrak akar dan antrakuinon utama daripada ekstrak akar mempunyai aktiviti antiplasmodial. Kajian semasa memperincikan pengoptimuman teknik pengekstrakan, analisis kualitatif dan kuantitatif terhadap sebatian terpilih dan aktiviti antiplasmodial *in vivo* disamping ujian toksik dan hambatan terhadap pembentukan β -hematin secara *in vitro*. Profil HPLC menunjukkan menunjukkan sebatian penanda sebagai sebatian utama dengan kandungan antara 3-12 $\mu\text{g/g}$ ekstrak. Ekstrak akar menunjukkan potensi aktiviti antiplasmodial terhadap jangkitan malaria tikus *Plasmodium berghei* dengan nilai ED_{50} 1.23 $\mu\text{g/ml}$ BB. Antrakuinon utama, damnakantal dan nordamnakantal menunjukkan aktiviti yang signifikan terhadap pembentukan β -hematin melalui pemangkinan lipid dan HRP2. Walau bagaimanapun, ekstrak akar didapati sedikit toksik terhadap sel hepatosit. Data sedia ada menunjukkan *R. elliptica* merupakan herba yang berpotensi untuk rawatan antimalaria dan aktiviti antiplasmodial

ekstrak akar berkemungkinan besar disebabkan aktiviti antrakuinon utama.

Kata kunci: *Rennellia elliptica*, antiplasmodial, antrakuinon, *Plasmodium*, malaria

© 2017 Penerbit UTM Press. All rights reserved

1.0 INTRODUCTION

Malaria affected 3.2 billion people with 584 000 deaths reported and 78 % were young children. The WHO program has seen to make an impressive progress on the reduction of total deaths; however, many are still at potential risk especially in the sub-Saharan Africa where 85% cases and deaths were reported [1]. Irrespective of this fact, only less than 1 % of health research was devoted to tropical diseases as most occurrences are in poor countries, and this links to unprofitability. Only 13 new drugs out of 1300 were introduced for parasitic diseases between 1975 and 1999 [2]. The dramatic increase in malarial infection is observed today resulting mainly from the widespread use of insecticide which has led to *Anopheles* mosquitoes resistance to insecticides as well as the increase in malarial protozoa resistance to the antimalarial drugs such as chloroquine [3, 4] and artemisinin. The parasite resistance against the only affordable drugs for use in resource limited regions such as chloroquine and sulfadoxine-pyrimethamine [5] complicates the efforts of eradicating malarial infection. Many newer drugs were synthetically derived from chloroquine and artemisinin to overcome the parasite resistance against these drugs. However, it was not long before the cross-resistance develops due to their structural similarity with the parent drugs [6].

Many people in low income nations often rely on traditional herbal remedy as first line treatment for malaria [7]. Medicinal plants such as *Morinda lucida* Benth [8], *Newbouldia laevis* [9], *Bulbine frutescens* [10], *Cassia siamea* [11], *Kniphofia foliosa* [12], *Stereospermum kunthianum* [13], *Tectona grandis* [14], *Pentas micrantha* [15], *Pentas longiflora* and *Pentas lanceolata* [16] are widely used in Africa for treatment of fever or malaria. Investigation on the antiplasmodial activity and active compounds of these plants yielded active metabolites with anthraquinones moiety. In South East Asia, about 210 species are listed for treatment of malaria [17].

Rennellia elliptica Korth. is a tropical shrub of about 1-2 m tall and can be found in lowland to hill forest to c. 500m above sea level. *R. elliptica* is locally known as 'mengkudu rimba' or 'segemuk' and popularly dubbed as Malaysian ginseng probably due to the appearance of its yellow roots. Among various Malaysian ethnics, this plant is also known as 'kayu penawar apow' (Dusun), 'mengkudu hutan' (Iban), 'akar bumi', 'urap gondor' (Sakai), 'mengkudu gajah', 'lempedu tanah' and 'sekemang' (Jah Hut, Semelai). *R. elliptica* is native to South East Asia and widely distributed in Peninsular

Malaysia, Southern Thailand, Borneo and Indonesia [18]. The decoction of *Rennellia elliptica* is traditionally taken for the treatment of jaundice [19] and body aches, as postpartum tonic and as aphrodisiac [20]. During the random screening of selected Malaysian tropical plants for antiplasmodial activity, *R. elliptica* showed promising activity (4.04 µg/ml) which warranted further investigation. Following the screening program, extensive phytochemical study was carried out on the root extract yielding eleven anthraquinones in which four of them were found to possess strong antiplasmodial activity with IC₅₀ values of less than 1 µM [21]. In order to establish the use of *R. elliptica* root extract of as potential herbal drug for the treatment of malaria, optimization of extraction methods, qualitative and quantitative HPLC analyses of the extract as well as the investigation of the extract toxicity and possible mechanism of actions are warranted. The chemotherapeutic targets selected were inhibition against β-hematin formation via lipids and HRP2 catalyses. Thus, this study aims to provide the data required to validate the safety and efficacy of the root extract of *R. elliptica* as potential antimalarial herbal drug.

2.0 METHODOLOGY

2.1 Plant Material

The roots of *Rennellia elliptica* Korth. were collected from Endau Rompin State Park, Pahang, Malaysia at an altitude of 165 m above sea level and were identified by Dr Shamsul Khamis of Universiti Putra Malaysia. The voucher specimen (SK1512/08) was deposited at Herbarium of the Institute of Bioscience, Universiti Putra Malaysia. The roots were air dried, cut into small pieces and ground to powder of about 1 mm mesh size using a grinder.

2.2 Optimization of Extraction

The dried root powder (10 g) was subjected to cold and soxhlet extraction using dichloromethane and ethanol. The dichloromethane extract (cold extraction) was used as control to compare the presence of marker anthraquinones with other extraction techniques. The filtrates were concentrated using rotary evaporator and kept in vial at 4°C for further analysis. For accelerated solvent extraction (Dionex ASE 150), 1 g of root powder was used every cycle (10 minutes) by

manipulating composition of ethanol and water at different temperature (H₂O: EtOH; 100: 0, 80: 20, 60 : 40, 40: 60, 20 : 80; Temperature, 60°C, 80°C, 100°C, 140°C) at a fixed pressure of 1000 psi. The filtrates were concentrated using freeze dryer. The percentage yield of root extract for different extraction technique was recorded. The root extracts were subjected to HPLC analyses to determine the presence of marker compounds.

2.3 Quantitative and Qualitative Analysis of Anthraquinones in *Rennellia Elliptica*

2.3.1 Sample Preparation

The root extract was dissolved in 100 µl CH₂Cl₂ and 900 µl MeCN:H₂O (9:1, v/v) at 10 mg/ml. The sample was passed through SepPak C-18 cartridge and Whatman nylon membrane filter (0.45 µM). The marker anthraquinones (nordamcanthal, damnacanthal, 2-formyl-3-hydroxy-9,10-anthraquinone, 2-methyl-3-hydroxy-9,10-anthraquinone and 1,2-dimethoxy-6-methyl,9-10-anthraquinone) were obtained from extensive chromatographic separation as reported previously [21].

2.3.2 HPLC Analysis

HPLC analysis was executed using a Waters HPLC W600 coupled with 2996 PDA detector system (Waters, USA) equipped with autosampler (2000 µl). Analysis was carried out at room temperature using Sunfire column (C-18 250 mm x 5 µM x 4.6 mm i.d., Waters, USA). The pump was connected to two mobile phases: A: H₂O and B: MeCN, and eluted at a flow rate of 1.0 ml/min. Formic acid (0.1 %) was added to the mobile phase. The mobile phase was programmed consecutively in a linear gradient as follows: 0-20 min, 60-35 % A; 21-40 min, 35-5 % A; 41-45 min, 5-0 % A; 46-60 min, 0 % A. The injection volume was 10 µL. The column temperature was maintained at room temperature. The peaks were monitored at spectral window 254-400 nm. The analyses were run in triplicates and standard deviation and coefficient of variance were calculated. The content of the compounds were expressed as microgram per gram of extract (µg/g) by correlating the area of the analyte with the calibration curve of standards built in concentrations of 20-140 mg/L using the generated equations: $y = 34904x - 973938$ adjusted $R^2 = 0.981303$ (nordamcanthal); $y = 12626x - 128752$ adjusted $R^2 = 0.978949$ (2-formyl-3-hydroxy-9,10-anthraquinone); $y = 11263 - 32993$ adjusted $R^2 = 0.946985$ (2-methyl-3-hydroxy-9,10-anthraquinone); $y = 91493x - (1E+6)$ adjusted $R^2 = 0.961946$ (1,2-dimethoxy-6-methyl,9-10-anthraquinone); $y = 12641x - 86520$ adjusted $R^2 = 0.946986$ (damnacanthal).

2.4 Antiplasmodial Activity using *Plasmodium berghei* in Animal Model

4-day suppressive assay was performed on albino male mice using chloroquine-sensitive *Plasmodium berghei* as described by Peters (1965) with slight modifications [22]. The mice were maintained on standard animal pallets and water *ad libitum*. The mice (mean body weight: 20 ± 2g) were infected intraperitoneally (i.p.) with 0.2 ml infected blood in saline containing about 1×10^7 *P. berghei* parasitized red blood cells at day 0. The mice were divided into groups of five per cage and the mice were administered orally with the sample immediately post infection for four consecutive days with three doses (1 mg/kg BW, 10 mg/kg BW, 100 mg/kg BW). The negative control group was treated with sodium carboxymethyl cellulose while the positive control group was treated with chloroquine diphosphate. On day 4 of the test, thin blood smears after tail blood sampling for each mouse were prepared and the blood film were fixed with methanol. The blood films were stained with Giemsa (Merck) and examined under microscope. The parasitemia was estimated by visual counting of at least 1000 erythrocytes. The antiplasmodial activity of each compound was expressed as an ED₅₀ value, defined as the concentration of the compound causing 50 % inhibition of parasite growth relative to an untreated control. The mice were maintained under institutional animal guidelines at the Department of Pharmacognosy and Phytochemistry, Universitas Airlangga, Indonesia.

2.4 β-Hematin Inhibitor Assay

2.4.1 Preparation of Heme Solution

Hemin chloride (16.3 mg) was dissolved in 1 ml of DMSO. The solution was passed through a 2.0-µm-pore membrane filter to remove insoluble particles. The solution can be kept at 4°C up to 1 month as a stock solution [23] and diluted to 50 µM heme with 500mM acetate buffer, pH 4.8, prior to analysis.

2.4.2 Screening for β-hematin Formation Assay

Chloroquine (500 µM) was used as the drug positive control. The compounds were dissolved in 100% DMSO to prepare a stock concentration of 10 mg/ml and 1 mg/ml. 110 µl of heme solution (50 µM), freshly buffered by 500 µM acetate buffer (pH 4.8) was pipeted and added into the microwell plate. Finally, lecithin (2 µg/ml) was added into each well. After incubation at 37°C for 16 h, the plate was read at 405 nm. The fraction (f) of heme converted to β-hematin was calculated as in a previous study [24]:

$$f = (A_{\text{control}} - A_{\text{sample}}) / (A_{\text{control}} - A_{\text{min}})$$

Where A_{control} is the absorbance of the heme without parasite lysate or lipid extract or an antimalarial at 405 nm, while A_{sample} represents the absorbance of the heme in the presence of both parasite lysate or lipid extract and plant extracts. A_{min} is the absorbance of the heme with parasite lysate or lipid extract in the absence of an antimalarial at 405 nm.

Percentage of inhibition of β -hematin by plant extracts was calculated by the following equations:

$$\% \text{ Inhibition} = (1-f) \times 100 = 100 \times (A_{\text{sample}} - A_{\text{min}}) / (A_{\text{control}} - A_{\text{min}})$$

2.4.3 HRP2 Assay

Antimalarial assay was carried out using HRP2 (HRP2 Kit Cellabs Pty. Ltd., Brookvale, New South Wales, Australia). Diluted extract solution (100 μL) and final parasite culture (100 μL) were added into the microplate. The plates were then incubated for 72 h at 37°C. They were subsequently frozen-thawed twice to obtain complete hemolysis and stored at 30°C until further processing. Each of the hemolyzed culture samples (100 μL) was transferred to the ELISA plates, which were pre-coated with monoclonal antibodies against *P. falciparum* HRP2. The plates were incubated at room temperature for 1 h in humidified chamber. The plates were washed five times with the washing solution (200 μL of each well) and 100 μL of the diluted antibody conjugate was added to each well. After incubation for an additional 1 h in humidified chamber, the plates were washed with washing solution (200 μL) and 100 μL of diluted (1:20) chromogen tetramethyl benzidine (TMB) was added to each well. The plates were then incubated for another 15 min in the dark and 50 μL of the stop solution was added. The optical density values were measured using ELISA microplate reader at an absorbance maximum of 450 nm. The percent inhibition was calculated using the following formula:



$$\% \text{ Inhibition} = (A_{\text{control}} - A_{\text{sample}}) / (A_{\text{well}}) \times 100$$

2.5 Toxicity Study

The cytotoxicity of the samples was assessed by MTT assay. Hepatocyte, Huh7it cells were treated with serial dilution of the samples in 96-well plates. The condition of the cells was observed after 46 hours incubation and the toxicity was observed under microscope. The medium was removed from 96 well plates and then 150 μL of MTT solution (10%) was added to each well and the plates were incubated for 4 hours at 37°C. MTT solution was removed from each well and 100 μL of DMSO was added to each well prior to shaking for 30 seconds. The absorbance was measured using ELISA microplate reader at 560 and 750 nm.

3.0 RESULTS AND DISCUSSION

Preparation of standardized extract is an authentication of herbal preparation as means of controlling the quality of plant material used for product manufacturing. The standardized extract should have an acceptable content of bioactive metabolites and safe from toxic impurities [25]. The present study included the establishment of the plant metabolites chemical profile of root extract using HPLC analyses. Nordamnacanthal **1**, damnacanthal **2**, 2-formyl-3-hydroxy-9,10-anthraquinone **3**, 2-methyl-3-hydroxy-9,10-anthraquinone **4** and 1,2-dimethoxy-6-methyl-9,10-anthraquinone **5** were selected as marker compounds due to their potent antiplasmodial activity [21]. In order to determine the composition of each biomarker in the root extract, external calibration curves were constructed using five point concentrations. The concentration of compounds **1**, **2**, **3**, **4** and **5** were determined at 3.57, 10.32, 4.47, 12.18 and 4.09 $\mu\text{g/g}$, respectively, with acceptable standard deviation ($\text{SD} < 0.2$) and coefficient of variance ($\text{CV} < 5\%$). It was evident from the chromatogram (Figure 1), the marker anthraquinones present as major compounds in the root extract, thus it is submitted that the antiplasmodial action of the root extract is potentially due to the action of these metabolites.



*The chromatogram was extracted at 276 nm.

Note: Rubiadin (4.848), Alizarin-1-methyl ether (7.815), 2-Hydroxy-3-methoxy-6-methyl-9,10-anthraquinone (22.477), 1-Hydroxy-2-methoxy-6-methyl-9,10-anthraquinone (23.279), 3-Hydroxy-2-methyl-9,10-anthraquinone (24.443), 2-formyl-3-hydroxy-9,10-anthraquinone (28.804), Damnacanthal (28.435), Lucidin- ω -methyl ether (34.066), 1,2-dimethoxy-6-methyl-9,10-anthraquinone (36.066), Nordamna-canthal (40.278). The unknown peaks at 10.104, 14.094, 16.547, 19.994 and 30.676 could be due to as rennellianone A and rennellianone B, scopoletin, 4-hydroxy-3,5-dimethoxybenzaldehyde and 3b-acetateoleanan-13b, 28-lactone [26].

Figure 1 HPLC Chromatogram of Dichloromethane Extract of *R. elliptica* Korth

In the previous study, dichloromethane root extract showed promising antiplasmodial activity [21]. However, dichloromethane is not a suitable extraction solvent for herbal preparation owing to the toxic properties of the solvent. Thus, the extraction of the dried root powder was attempted using ethanol and water in soxhlet and accelerated solvent extraction (ASE). Dichloromethane extract was also prepared as control to compare the presence of selected marker compounds. The extracts were then analyzed for the presence of selected biomarkers using Waters HPLC system. The accelerated solvent extraction (20: 80, H₂O: EtOH; 100 °C) gave the comparable amount and quality of marker anthraquinones in the root extract as compared to dichloromethane extract (Table 1). The use of ethanol in cold and soxhlet extraction did not successfully extract the desired biomarkers compounds. The ASE can reduce the polarity of water and ethanol because high pressure and temperature will reduce the dielectric constant of water, which lowers its polarity and assists the extraction of more non-polar compounds [27, 28].

Table 1 Optimization of Extraction of Root Extract of *Rennellia elliptica*

Type of extraction	Solvent/Condition	%Yield
Cold extraction (10g)	Dichloromethane (3 days)	0.97
	Ethanol (3 days)	2.07
Sohxlet Extraction (10 g)	Dichloromethane (2 hours)	0.58
	Ethanol (2 hours)	2.28
Accelerated solvent extraction (1g)	100 : 0 (H ₂ O:EtOH), 60°C, 10 min	0.55
	50 : 50 (H ₂ O:EtOH), 60°C, 10 min	2.43
	20 : 80 (H ₂ O:EtOH), 60°C, 10 min	3.03
	20 : 80 (H ₂ O:EtOH), 80°C, 10 min	0.52
	20 : 80 (H ₂ O:EtOH), 100°C, 10 min	0.3
	20 : 80 (H ₂ O:EtOH), 140°C, 10 min	0.5

The screening of dichloromethane extract for antiplasmodial activity *in vitro* showed promising activity with IC₅₀ value of 4.04 µg/ml [21]. Crude extracts with IC₅₀ values of less than 50 µg/ml are considered effective as antiplasmodial agents [29]. Thus, the antiplasmodial activity of the extract was further evaluated in a 4-day suppressive test using *P. berghei* (ANKA strain) infected mice. The dichloromethane extract showed very strong activity with an ED₅₀ value of 1.23 µg/ml.

The toxicity study was carried out to determine the selectivity of the root extract and marker compounds against the hepatocyte cell. The dichloromethane root extract showed mild toxicity with CC₅₀ value of 318.0 µg/ml (Table 2). For both *in vitro* and *in vivo* studies, the selectivity indexes were determined at 78.7 and 258.3, respectively. The selected biomarkers showed no toxicity except 2-formyl-3-hydroxy-9,10-anthraquinone, nordamnanthal and damnanthal which showed moderate toxicity with CC₅₀ values of 181.34, 908.96 and 338.65 µM, respectively, with moderate selectivity index (Table 2). Thus, traditional

preparation of the decoction of the root should be used with caution. Further study is required to assess the safety use of *R. elliptica* in traditional preparation.

One of the important chemotherapeutic targets in combating malaria infection is its food vacuole. The malaria parasite digests erythrocytes and releases heme [30] along with oxygen [31]. Free heme is toxic owing to its detergent-like properties that destabilizes and lyses membranes [6, 32], as well as inhibits the activity of several enzymes such as cysteine proteases [32] and consequently leads to the death of the parasite. The mechanism of heme detoxification can be broadly classified into two types; primarily via dimerization into hemozoin and secondarily via degradation of heme by glutathione and hydrogen peroxide [33]. Histidine-rich protein II (HRP2) [31, 32] and lipids [33] are proposed to catalyze the reaction but there are other evidences that the hemozoin formation may be spontaneous [34] and autocatalytic [35]. Drugs such as quinine and chloroquine which targeted the prevention of β-hematin formation have a longer lifespan of effective use against malarial parasite. The parasite seems to have difficulties in finding alternative processes for haemoglobin utilization and heme detoxification as compared to other chemotherapeutic targets [36].

Table 2 The toxicity, β- hematin and HRP2 Assays of the root extract and selected compounds

AQ	Toxicity CC ₅₀ µM	Antiplasmodial in vitro IC ₅₀ µM*	Selectivity index	β-hematin IC ₅₀ µM	HRP2 IC ₅₀ µM
1	908.96	72.46	12.5	67.16 ± 0.2	4.37
2	338.65	51.28	6.6	5.32 ± 0.2	11.77
3	181.34	0.63	285.6	158.73 ± 0.2	nt
4	>3968.3	0.34	12,500	138.65±0.1	nt
5	>3546.1	1.1	3225	na	na
Root	318.0†	4.04†	78.7	nt	nt

*Extracted from Osman et al. (2010)

nt- not tested; na- no activity

† - unit µg/ml

In the present study, the biomarkers were probed for their possible mode of action against β-hematin formation. Damnanthal **1** and nordamnanthal **2** showed significant inhibition against hemozoin formation via HRP2 and lipids catalyses (Table 2). It is interesting to note that the damnanthal **1** and nordamnanthal **2** showed weaker activity when tested against *Plasmodium falciparum* (3D7 strain) *in vitro* as compared to 2-formyl-3-hydroxy-9,10-anthraquinone **3** and 2-methyl-3-hydroxy-9,10-anthraquinone **4** [21]. 2-Formyl-3-hydroxy-9,10-anthraquinone **3** and 2-methyl-3-hydroxy-9,10-anthraquinone **4** showed the strongest antiplasmodial activity *in vitro* and their mode of action are yet to be discovered.

4.0 CONCLUSION

Rennellia elliptica is a potential herbal remedy against malarial infection and its activity possibly contributed by the major anthraquinones in the root. One of the identified modes of action is inhibition against β -hematin formation as shown by the marker compounds, nordamcanthal and damnacanthal. The mode of action of other marker compounds is yet to be determined. The root extract showed slight toxicity against normal cell with high selectivity towards *Plasmodium falciparum*.

Acknowledgement

The authors would like to thank Ministry of Higher Education for financial support under Fundamental Research Grant Scheme (600-RMI/FRGS 5/3/(5/2013) and Universiti Teknologi MARA for the use of research facilities. The authors also wish to thank Dr Shamsul Khamis from Universiti Putra Malaysia for plant identification.

References

- [1] WHO. 2014. World Malaria Report 2014. ed. Switzerland: WHO, 2014.
- [2] Pink, R., A. Hudson, M.-A. Mouries, and M. Bendig. 2005. Opportunities and Challenges in Antiparasitic Drug Discovery, *Nature Reviews Drug Discovery*. 4 (9): 727-740
- [3] Mambu, L. and P. Grellier. 2007. Antimalarial Compounds from Traditionally Used Medicinal Plants. in *Bioactive Natural Products: Detection, Isolation and Structural Determination*. S. M. Colegate and R. J. Molyneux, Eds. 2th Florida: CRC Press.
- [4] Phillipson, J. D. and C. W. Wright. 1991. Can Ethnopharmacology Contribute To The Development Of Antimalarial Agents? *Journal of Ethnopharmacology*. 32(1-3): 155-165.
- [5] Biagini, G. A., P. M. O'Neill, A. Nzila, S. A. Ward, and P. G. Bray. 2003. Antimalarial Chemotherapy: Young Guns or Back to the Future? *Trends In Parasitology*. 19 (11): 479-487.
- [6] Cowman, A. F. and S. J. Foote. 1990. Chemotherapy and Drug Resistance in Malaria. *International Journal for Parasitology*. 20(4): 503-513.
- [7] Dharani, N., G. Rukunga, A. Yenesew, A. Mbora, L. Mwaura, I. Dawson, et al. 2010. *Common Antimalarial Trees and Shrubs of East Africa : a Description of Species and a Guide to Cultivation and Conservation Through Use*. Nairobi, Kenya: The World Agroforestry Centre (ICRAF).
- [8] Sittie, A. A., E. Lemmich, C. E. Olsen, L. Hviid, A. Kharazmi, F. K. Nkrumah, et al. 1999. Structure-activity Studies: *In vitro* Antileishmanial and Antimalarial Activities of Anthraquinones from *Morinda lucida*. *Planta Medica*. 65: 259-261.
- [9] Eyong, K. O., G. N. Folefoc, V. Kuete, V. P. Beng, K. Krohn, H. Hussain, et al. 2006. Newbouldiaquinone A: A Naphthoquinone-anthraquinone Ether Coupled Pigment, as a Potential Antimicrobial and Antimalarial Agent from *Newbouldia laevis*. *Phytochemistry*. 67(6): 605-609.
- [10] Abegaz, B. M., M. Bezabih, T. Msufa, R. Brun, D. Menche, J. Muhlbacher, et al. 2002. Gaboroquinones A and B and 4'-O-Demethylknipholone-4'-O-b-D-glucopyranoside, Phenylanthraquinones from the Roots of *Bulbine frutescens*. *Journal of Natural Products*. 65(8): 1117-1121.
- [11] Ajaiyeoba, E. O., J. S. Ashidi, P. J. Houghton, and C. W. Wright. 2008. Antiplasmodial Compounds from *Cassia siamea* Stem Bark Extract, *Phytotherapy Research*. 22(2): 254-255.
- [12] Abdissa, N., M. Induli, H. M. Akala, M. Heydenreich, J. O. Midiwo, A. Ndakala, et al. 2013. Knipholone Cyclooxanthrone and an Anthraquinone Dimer with Antiplasmodial Activities from the Roots of *Kniphofia foliosa*. *Phytochemistry Letters*. 6(2): 241-245.
- [13] Onegi, B., C. Kraft, I. Köhler, M. Freund, K. Jenett-Siems, K. Siems, et al. 2002. Antiplasmodial Activity of Naphthoquinones and One Anthraquinone from *Stereospermum kunthianum*, *Phytochemistry*. 60 (1): 39-44.
- [14] Kopa, T. K., A. T. Tchinda, M. F. Tala, D. Zofou, R. Jumbam, H. K. Wabo, et al. 2014. Antiplasmodial Anthraquinones and Hemisynthetic Derivatives from the Leaves of *Tectona Grandis* (Verbenaceae). *Phytochemistry Letters*. 8: 41-45
- [15] Endale, M., A. Ekberg, J. Alao, H. Akala, A. Ndakala, P. Sunnerhagen, et al. 2012. Anthraquinones of the Roots of *Pentas micrantha*. *Molecules*. 18(1): 311.
- [16] Endale, M., J. P. Alao, H. M. Akala, N. K. Rono, S. Derese, A. Ndakala, et al. 2012. Antiplasmodial Quinones from *Pentas longiflora* and *Pentas lanceolata*. *Planta Medica*. 78(1): 31-35
- [17] Burkill, I. H. 1966. *A Dictionary of the Economic Products of Malay Peninsular*. Kuala Lumpur: Ministry of Agriculture.
- [18] Wong, K. M. 1989. Rubiaceae (from the genus *Rubia*). in *Tree Flora of Malaya; A Manual for Foresters*. vol. 4, F. S. P. Ng, Ed.: Longman Malaysia.
- [19] Ismail, I., A. C. Linatoc, M. Mohamed, and L. Tokiman. 2015. Documentation of Medicinal Plants Traditionally Used by the Jakun People of Endau-Rompin (PETA) for Treatments of Malaria-Like Symptoms, *Jurnal Teknologi*. 77(31): 63-69.
- [20] Yusoff, N. I., J. Latip, H. L. Liew, and A. Latiff. 2004. Kajian Fitokimia Awal Tumbuhan Taman Negeri Endau Rompin, Pahang: Antrakuinon daripada Akar *Rennellia elliptica* Korth. (Rubiaceae). *Taman Endau Rompin: Pengurusan Persekitaran Fizikal dan Biologi*, S. Mohamad Ismail, M. Mat Isa, W. Y. W. Ahmad, M. R. Ramli, and A. Latiff, Eds.: Jabatan Perhutanan Semenanjung Malaysia.
- [21] Osman, C. P., N. H. Ismail, R. Ahmad, N. Ahmat, K. Awang, and F. M. Jaafar. 2010. Anthraquinones with Antiplasmodial Activity from the Roots of *Rennellia elliptica* Korth. (Rubiaceae). *Molecules*. 15(10): 7218-7226.
- [22] Peters, W. 1965. Drug Resistance in *Plasmodium berghei*. I. Chloroquine Resistance. *Experimental Parasitology*. 17(1): 80-89.
- [23] Xuan Trang, D. T., N. T. Huy, D. T. Uyen, M. Sasai, T. Shiono, S. Harada, et al. 2006. Inhibition Assay of β -hematin Formation Initiated By Lecithin For Screening New Antimalarial Drugs. *Analytical Biochemistry*. 349(2): 292-296.
- [24] Huy, N. T., D. T. Uyen, M. Sasai, D. T. X. Trang, T. Shiono, S. Harada, et al. 2006. A Simple and Rapid Colorimetric Method to Measure Hemozoin Crystal Growth in Vitro. *Analytical Biochemistry*. 354(2): 305-307.
- [25] Jamal, J. A. 2006. Malay Traditional Medicine; An Overview of Scientific and Technological Progress. *TECH Monitor*. 37-49.
- [26] Osman, C. P., N. H. Ismail, A. Wibowo, and R. Ahmad. 2016. Two New Pyranoanthraquinones from the Root of *Rennellia Elliptica* Korth. (Rubiaceae). *Phytochemistry Letters*. 16: 225-229.
- [27] Rodríguez-Meizoso, I., F. R. Marin, M. Herrero, F. J. Señorans, G. Reglero, A. Cifuentes, et al. 2006. Subcritical Water Extraction of Nutraceuticals with Antioxidant Activity from Oregano. Chemical and functional characterization, *Journal of Pharmaceutical and Biomedical Analysis*. 41(5): 1560-1565.
- [28] Ju, Z. Y. and L. R. Howard. 2003. Effects of Solvent and Temperature on Pressurized Liquid Extraction of

- Anthocyanins and Total Phenolics from Dried Red Grape Skin, *Journal of Agricultural and Food Chemistry*. 51(18): 5207-5213.
- [29] Kohler, I., K. Jenett-Siems, K. Siems, M. A. Hernandez, R. A. Ibarra, W. G. Berendsohn, et al. 2002. *In Vitro* Antiplasmodial Investigation of Medicinal Plants from El Savador. *Z. Naturforsch.* 57c: 277-278.
- [30] Egan, T. J. 2003. Haemozoin (malaria pigment): A Unique Crystalline Drug Target. *TARGETS*. 2(3): 115-124.
- [31] Sullivan, D. J. 2002. Theories on Malarial Pigment Formation And Quinoline Action. *International Journal for Parasitology*. 32(13): 1645-1653.
- [32] Kumar, S., M. Guha, V. Choubey, P. Maity, and U. Bandyopadhyay. 2007. Antimalarial Drugs Inhibiting Hemozoin (B-Hematin) Formation: A Mechanistic Update. *Life Sciences*. 80(9): 813-828.
- [33] Rathore, D., D. Jani, R. Nagarkatti, and S. Kumar. 2006. Heme Detoxification and Antimalarial Drugs - Known Mechanisms and Future Prospects. *Drug Discovery Today: Therapeutic Strategies*. 3(2): 153-158.
- [34] Egan, T. J., J. Y.-J. Chen, K. A. de Villiers, T. E. Mabothe, K. J. Naidoo, K. K. Ncokazi, et al. 2006. Haemozoin (beta-haematin) Biomineralization Occurs by Self-assembly Near the Lipid/Water Interface. *FEBS Letters*. 580: 5105-5110.
- [35] Kumar, S. and U. Bandyopadhyay. 2005. Free Heme Toxicity and Its Detoxification Systems in Human. *Toxicology Letters*. 157(3): 175-188.
- [36] Olliaro, P. L. and Y. Yuthavong. 1999. An Overview of Chemotherapeutic Targets for Antimalarial Drug Discovery, *Pharmacology & Therapeutics*. 81(2): 91-110.